|
PRKAG2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62725388719309E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.00974784089658E-12 |
| Normal-vs-Stage2 |
8.11279999846093E-08 |
| Normal-vs-Stage3 |
6.68339827925024E-11 |
| Normal-vs-Stage4 |
4.44089209850063E-16 |
| Stage1-vs-Stage2 |
8.598200E-01 |
| Stage1-vs-Stage3 |
6.169400E-01 |
| Stage1-vs-Stage4 |
3.632200E-04 |
| Stage2-vs-Stage3 |
6.237200E-01 |
| Stage2-vs-Stage4 |
1.591590E-02 |
| Stage3-vs-Stage4 |
1.668230E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
1.34360000003664E-06 |
| Normal-vs-Asian |
1.86850535044414E-11 |
| Caucasian-vs-AfricanAmerican |
8.514200E-01 |
| Caucasian-vs-Asian |
6.366200E-01 |
| AfricanAmerican-vs-Asian |
6.432200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.93178806284777E-14 |
| Normal-vs-Female |
1.81632486828676E-12 |
| Male-vs-Female |
4.386400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.80289116968879E-12 |
| Normal-vs-Age(41-60Yrs) |
8.33999536098418E-13 |
| Normal-vs-Age(61-80Yrs) |
6.11789996440848E-09 |
| Normal-vs-Age(81-100Yrs) |
6.965800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.636800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.585600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.322800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.321200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.557000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.354600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.356400E-02 |
| Classical-VS-Follicular |
1.140760E-01 |
| Classical-VS-Other |
8.542400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
8.043100E-03 |
| Tall-VS-Other |
6.589400E-01 |
| Tall-VS-Normal |
6.59139409719955E-13 |
| Follicular-VS-Other |
9.322400E-01 |
| Follicular-VS-Normal |
2.79739999997641E-06 |
| Other-VS-Normal |
2.787200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.69759994950169E-09 |
| Normal-vs-N1 |
1.62481139653892E-12 |
| N0-vs-N1 |
2.565600E-04 |
|
|
